263 related articles for article (PubMed ID: 20106868)
1. Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm.
Royer-Pokora B; Busch M; Beier M; Duhme C; de Torres C; Mora J; Brandt A; Royer HD
Hum Mol Genet; 2010 May; 19(9):1651-68. PubMed ID: 20106868
[TBL] [Abstract][Full Text] [Related]
2. Canonical WNT signalling determines lineage specificity in Wilms tumour.
Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
[TBL] [Abstract][Full Text] [Related]
3. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
4. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
[TBL] [Abstract][Full Text] [Related]
6. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
Roberts DJ; Haber D; Sklar J; Crum CP
Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors.
Ruteshouser EC; Hendrickson BW; Colella S; Krahe R; Pinto L; Huff V
Genes Chromosomes Cancer; 2005 Jun; 43(2):172-80. PubMed ID: 15761866
[TBL] [Abstract][Full Text] [Related]
8. Target genes of the WNT/beta-catenin pathway in Wilms tumors.
Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M
Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872
[TBL] [Abstract][Full Text] [Related]
9. Wilms tumor and the WT1 gene.
Lee SB; Haber DA
Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
[TBL] [Abstract][Full Text] [Related]
10. Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1.
Sim EU; Smith A; Szilagi E; Rae F; Ioannou P; Lindsay MH; Little MH
Oncogene; 2002 May; 21(19):2948-60. PubMed ID: 12082525
[TBL] [Abstract][Full Text] [Related]
11. Two molecular subgroups of Wilms' tumors with or without WT1 mutations.
Schumacher V; Schuhen S; Sonner S; Weirich A; Leuschner I; Harms D; Licht J; Roberts S; Royer-Pokora B
Clin Cancer Res; 2003 Jun; 9(6):2005-14. PubMed ID: 12796362
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
Udtha M; Lee SJ; Alam R; Coombes K; Huff V
Oncogene; 2003 Jun; 22(24):3821-6. PubMed ID: 12802290
[TBL] [Abstract][Full Text] [Related]
13. Fusion of the EWS1 and WT1 genes as a result of the t(11;22)(p13;q12) translocation in desmoplastic small round cell tumors.
Benjamin LE; Fredericks WJ; Barr FG; Rauscher FJ
Med Pediatr Oncol; 1996 Nov; 27(5):434-9. PubMed ID: 8827070
[TBL] [Abstract][Full Text] [Related]
14. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.
Koesters R; Ridder R; Kopp-Schneider A; Betts D; Adams V; Niggli F; Briner J; von Knebel Doeberitz M
Cancer Res; 1999 Aug; 59(16):3880-2. PubMed ID: 10463574
[TBL] [Abstract][Full Text] [Related]
15. Neural crest and mesoderm lineage-dependent gene expression in orofacial development.
Bhattacherjee V; Mukhopadhyay P; Singh S; Johnson C; Philipose JT; Warner CP; Greene RM; Pisano MM
Differentiation; 2007 Jun; 75(5):463-77. PubMed ID: 17286603
[TBL] [Abstract][Full Text] [Related]
16. Functional properties of WT1.
Haber DA; Englert C; Maheswaran S
Med Pediatr Oncol; 1996 Nov; 27(5):453-5. PubMed ID: 8827073
[TBL] [Abstract][Full Text] [Related]
17. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
[TBL] [Abstract][Full Text] [Related]
18. Exclusion of the Wilms tumour gene (WT1) promoter as a site of frequent mutation in Wilms tumour.
Grubb GR; Yun K; Reeve AE; Eccles MR
Oncogene; 1995 Apr; 10(8):1677-81. PubMed ID: 7731725
[TBL] [Abstract][Full Text] [Related]
19. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
[TBL] [Abstract][Full Text] [Related]
20. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
Wu R; Zhai Y; Fearon ER; Cho KR
Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]